Successful repurposing of empagliflozin to treat neutropenia in a severe congenital neutropenia patient with G6PC3 mutations
- PMID: 39557394
- DOI: 10.1016/j.metabol.2024.156077
Successful repurposing of empagliflozin to treat neutropenia in a severe congenital neutropenia patient with G6PC3 mutations
Keywords: Empagliflozin; G6PC3; SGLT-2 inhibitor; Severe congenital neutropenia.
Conflict of interest statement
Declaration of competing interest All authors declare that they have no conflict of interests. In specific, all authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.
Publication types
LinkOut - more resources
Full Text Sources